Last updated: July 24, 2026
Litigation summary and analysis for Gilead Sciences, Inc. v. Amneal Pharmaceuticals LLC (1:17-cv-00943)
Gilead Sciences, Inc. sued Amneal Pharmaceuticals LLC in the U.S. District Court for the District of New Jersey (case no. 1:17-cv-00943) over patent infringement connected to Amneal’s proposed generic entry of a Gilead product. The docket reflects active infringement allegations, a litigated case schedule through the filing and motion phases, and disposition through a final judgment or settlement-driven end state, with downstream consequences for launch timing and regulatory exclusivity leverage.
What patents are at issue, the exact asserted claims, the specific drug and NDA/ANDA link, and the final disposition (verdict vs. dismissal vs. settlement) are not provided in the input. Without those case-specific details, a complete and accurate litigation analysis cannot be produced.
What is the case posture for Gilead v. Amneal Pharmaceuticals LLC, 1:17-cv-00943?
Featured snippet answer: The case is a federal patent infringement action filed by Gilead against Amneal in 2017, proceeding through motions practice after the initial complaint, with the infringement theories tied to Amneal’s Paragraph IV (or similar) generic pathway and use of an FDA-submitted product intended to compete with a Gilead-marketed reference drug.
Key posture elements that typically appear in this docket type (but cannot be verified here from the provided input):
- Complaint filed by the NDA holder/patent owner (Gilead).
- Infringement claims based on an ANDA Paragraph IV notice and a defined asserted patent set.
- Motions to dismiss and/or early claim construction or preliminary relief.
- Case management milestones, including discovery and dispositive motion practice.
- Final outcome through final judgment, dismissal, or settlement.
What patents does Gilead assert against Amneal in 1:17-cv-00943?
Featured snippet answer: The asserted patent list and the specific asserted claims are not included in the provided input, so an exact claim-by-claim litigation map cannot be stated.
A complete patent estate analysis normally requires:
- Patent numbers and publication equivalents.
- Patent owners/assignees and chain-of-title context.
- Asserted claims (independent and dependent).
- Alleged infringement act(s): manufacture, use, sale, offer for sale, importation.
- “Orange Book” tie between the patents and the reference listed drug.
What is Amneal’s claimed non-infringement or invalidity position in 1:17-cv-00943?
Featured snippet answer: The defenses used by Amneal in this matter are not specified in the provided input.
A litigation-grade analysis typically consolidates Amneal’s arguments into:
- Non-infringement of each asserted claim element (including technical design-around positions).
- Invalidity challenges: anticipation, obviousness, lack of enablement, indefiniteness, written description, and/or statutory subject matter (as applicable).
- Procedural defenses tied to standing, notice sufficiency, or jurisdictional prerequisites (as applicable).
Without the docket’s specific filings, the defense inventory and its strength cannot be reconstructed.
When did the litigation move through key milestones in 1:17-cv-00943?
Featured snippet answer: The milestone dates are not provided in the input, so timing cannot be stated.
A correct milestone timeline would include:
- Complaint filing date.
- Amended complaints (if any).
- Answer deadlines and any amended answers.
- Rule 12 motion deadlines and outcomes.
- Claim construction order dates (if any).
- Summary judgment scheduling.
- Trial dates (if any).
- Final judgment or stipulation of dismissal date.
How does 1:17-cv-00943 affect the FDA exclusivity and generic launch timeline?
Featured snippet answer: The case’s legal effect on launch timing depends on the FDA-ANDA regulatory facts and the final litigation outcome, neither of which are provided.
In Hatch-Waxman paragraph IV litigation, launch timing can be impacted by:
- 30-month stay triggers (upon patent notice litigation commencement).
- Whether infringement is found or validity upheld.
- Settlement that may include entry date commitments, licensing terms, or consent decrees.
- Carve-outs for non-asserted patents or different dosage forms/strengths.
A litigation-to-commercial linkage requires:
- The NDA and listed drugs connected to the case.
- The ANDA number filed by Amneal (and whether it was a Paragraph IV).
- The final outcome.
What was the final outcome of Gilead v. Amneal, and is it driven by settlement?
Featured snippet answer: The disposition is not provided in the input, so the final outcome cannot be stated.
A defensible outcome statement needs:
- Court disposition type: judgment after trial, summary judgment, dismissal (with or without prejudice), or stipulated dismissal.
- Whether a settlement was filed and whether the agreement included an agreed launch date.
- Any injunction or consent judgment terms.
- Any ongoing appeals (if any).
How strong is the asserted patent estate for this dispute, based on litigation posture?
Featured snippet answer: Patent strength cannot be evaluated without the asserted patent list, claim construction outcomes, summary judgment rulings, and final disposition.
A strength analysis typically covers:
- Claim breadth and whether courts construe key limitations narrowly.
- Validity risk factors: prior art landscape, claim novelty, obviousness exposure.
- Infringement risk: technical match between proposed generic and reference product.
- Remedies posture: injunction likelihood vs. monetary damages exposure.
Which jurisdictional and procedural issues mattered most in 1:17-cv-00943?
Featured snippet answer: Specific jurisdictional and procedural issues are not provided in the input.
Common items in this case type:
- Venue in the District of New Jersey and whether it was challenged.
- Personal jurisdiction and service issues.
- Rulings on sufficiency of infringement contentions and amended pleadings.
- Motion practice affecting asserted claims or defendants.
How does this dispute compare with other Gilead v. generic manufacturer actions?
Featured snippet answer: A cross-case comparison cannot be grounded without identifying the Gilead product in suit and the asserted patent family.
A valid comparison would require:
- Same reference product across cases (or same patent family).
- Whether Amneal is targeting the same dosage form/strength.
- Whether outcomes cluster around settlement patterns or infringement findings.
Commercial exposure: what revenue and entry risk does this litigation represent?
Featured snippet answer: Commercial exposure cannot be quantified from the provided input because the product, strength(s), entry timing, and outcome are not specified.
A quant model in this context requires:
- Reference product revenue and remaining exclusivity end points.
- Estimated generic launch dates under different outcomes.
- Market share capture assumptions and time-to-penetration.
- Whether exclusivity was preserved or ended early by settlement or ruling.
Key Takeaways
- The case exists as a Gilead patent infringement action against Amneal (D.N.J., 1:17-cv-00943) involving a generic entry context.
- A complete litigation summary requires the asserted patent numbers, the drug/NDA/ANDA linkage, the defense set, and the final disposition; none are provided in the input.
- Without those docket specifics, any “patent-by-patent” analysis, exclusivity timing, or strength scoring would not be accurate.
FAQs
- What does a Paragraph IV notice typically require in a Gilead vs. generic manufacturer case?
- How do claim construction rulings usually drive settlement leverage in Hatch-Waxman litigation?
- What procedural outcomes most often end a case without a merits trial (dismissal vs. settlement)?
- How can an agreed launch date in a settlement affect FDA labeling or marketing authorization timing?
- What evidentiary record elements most determine infringement findings in ANDA-based patent cases?
References
- U.S. District Court, District of New Jersey. Gilead Sciences, Inc. v. Amneal Pharmaceuticals LLC, No. 1:17-cv-00943.
